Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Slides:

Advertisements

Similar presentations

Philip J. Barter, et al. Circulation 2011;124:

Advertisements

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA)

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Postprandial glucose flux in nondiabetic controls.

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

Glucose, insulin, and AGE levels during an OGC before and after RT

Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

HRs for prostate cancer by medication status.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

The underlying physiological basis of the HOMA model.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

RBC counts (A), hemoglobin (B), MCH (C), serum transferrin (Tf) saturation (D), and serum ferritin (E) in 47 pregnant women (study 1) divided according.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Relationship between changes in mean fat cell volume and insulin sensitivity (M values) after gastric bypass of obese women. Relationship between changes.

Effect of empagliflozin on efficacy parameters at week 18.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Correlations between leptin DNA methylation and 2-h post-OGTT glucose levels, within the IGT group (A and B), leptin DNA methylation and mRNA levels (C.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

RBP4 and glucose metabolism.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Distribution of daily frequency of BGM

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Postoperative blood glucose levels and total insulin requirement.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Plasma concentration of metabolite M1 (left panel), glucose infusion rate (GIR) to maintain euglycemia (middle panel), and blood glucose concentration.

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

A: Detection of insulin aspart and insulin lispro by the Iso-insulin ELISA method. A: Detection of insulin aspart and insulin lispro by the Iso-insulin.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The use of a glucose analog (18F-deoxyglucose) and positron emission tomography images of the left ventricular wall of the heart of a normal subjects (left).

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

A: Glucose levels during basal-bolus and SSI treatment.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia in seven patients with T1DM. Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia in seven patients with T1DM. Shown are means ± SE. Statistical analysis: *P < 0.02 compared with 0 h. Right columns: Plasma glucose, serum insulin, circulating TF-PCA, and FVIIa levels before and during 10 h of combined hyperglycemia plus hyperinsulinemia in eight patients with T1DM and in seven nondiabetic control subjects (open circles). Shown are means ± SE. Statistical analysis: TF-PCA *P < 0.01 compared with baseline. FVIIa: *P < 0.05; **P < 0.01 compared with baseline. Anamika Singh et al. Dia Care 2012;35:1322-1327 ©2012 by American Diabetes Association